CAJ | 학술논문

目的探讨全身应用重组人促红细胞生成索(rhEPO)对急性高眼压兔眼视网膜bcl-2蛋白表达的影响及意义.方法在设立正常对照、急性高眼压模型对照的情况下,日本大耳白兔皮下注射rhEPO,分别于造模后第1、3、7、14天免疫组化法观察视网膜bcl-2蛋白表达.结果正常视网膜组织可见bcl-2蛋白表达,染色阳性细胞数为每高倍视野(10.5±1.2)个.模型组和EPO组兔眼视网膜bcl-2蛋白表达阳性细胞数均较正常对照组减少(P<0.05,P<0.01).EPO组第7天、14天视网膜bcl-2蛋白表达阳性细胞数较模型组增加(P<0.05,P<0.01).结论 rhEPO可以上调视网膜bcl-2蛋白表达,这可能是rhEPO保护急性高眼压引起的兔眼视网膜神经功能损害的机制之一.
목적 탐토전신응용중조인촉홍세포생성색(rhEPO)대급성고안압토안시망막bcl-2단백표체적영향급의의.방법 재설립정상대조、급성고안압모형대조적정황하,일본대이백토피하주사rhEPO,분별우조모후제1、3、7、14천면역조화법관찰시망막bcl-2단백표체.결과 정상시망막조직가견bcl-2단백표체,염색양성세포수위매고배시야(10.5±1.2)개.모형조화EPO조토안시망막bcl-2단백표체양성세포수균교정상대조조감소(P<0.05,P<0.01).EPO조제7천、14천시망막bcl-2단백표체양성세포수교모형조증가(P<0.05,P<0.01).결론 rhEPO가이상조시망막bcl-2단백표체,저가능시rhEPO보호급성고안압인기적토안시망막신경공능손해적궤제지일.
Objective To investigate the effect of recombinant human erythropoietin (rhEPO) on the expression of bcl-2 protein in the retina of rabbits with acute high intraocular pressure and explore the mechanism underlying the protective effect of rhEPO on the retina against ischemia-reperfusion injury. Methods rhEPO was injected subcutaneously in the ear of a rabbit model of acute high intraocular pressure induced by physiological saline perfusion into the anterior chamber. Bcl-2 protein expression in the retina of the rabbits was observed by immunohistochemical staining on days 1, 3, 7, and 14 after retinal ischemia-reperfusion and compared with that in normal rabbits and untreated rabbit models. Results bcl-2-positive cells were observed in the retina of normal rabbits with a mean positive cell number of 10.5 ±1.2 in each high-power visual field. Compared with that in the normal control group, the number of the positive cells decreased significantly in both the model group and EPO group (P<0.05, P<0.01), but the latter group showed a significantly greater number than the former (P<0.05 at day 7 and P<0.01 at day 14). Conclusion Systemic administration of rhEPO can up-regulate the expression ofbcl-2 protein in the retina of rabbits with acute high intraocular pressure, which is probably one of the mechanisms for the protective effect of rhEPO on the retina against ischemia-repeffusion injury.